Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Turkova, AnnaBwakura-Dangarembizi, Mutsa F.Kekitiinwa, Adeodata R.Lugemwa, AbbasAhimbisibwe, Grace MiriamBurger, David M.2025-02-192025-02-192022-07-19Turkova, A., Waalewijn, H., Chan, M. K., Bollen, P. D., Bwakura-Dangarembizi, M. F., Kekitiinwa, A. R., ... & Greetanukroh, P. (2022). Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. The Lancet HIV, 9(9), e627-e637.https://doi.org/10.1016/ S2352-3018(22)00160-6https://nru.uncst.go.ug/handle/123456789/9969Children with HIV-associated tuberculosis (TB) have few antiretroviral therapy (ART) options. We aimed to evaluate the safety and pharmacokinetics of dolutegravir twice-daily dosing in children receiving rifampicin for HIV-associated TB.enDolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trialArticle